US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ARIAD Pharmaceuticals

23.99

0.0000

Volume:- -

Turnover:- -

Market Cap:4.66B

PE:-133.28

High:23.99

Open:23.99

Low:23.99

Close:23.99

52wk High:23.99

52wk Low:23.99

Shares:194.20M

Float Shares:169.70M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.1800

ROE:--

ROA:--

PB:-100.52

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ARIA"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ARIA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARIA\",,,,,undefined,":{"symbol":"ARIA","market":"US","secType":"STK","nameCN":"ARIAD Pharmaceuticals","latestPrice":23.99,"timestamp":1757361600000,"preClose":23.99,"halted":0,"volume":0,"delay":0,"floatShares":169700000,"shares":194200862,"eps":-0.18,"marketStatus":"Pre-Mkt","change":0,"latestTime":"09-09 06:42:31 EDT","open":23.99,"high":23.99,"low":23.99,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.18,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1757424600000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":23.99,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARIA\",,,,,undefined,":{"symbol":"ARIA","floatShares":169700000,"roa":"--","roe":"--","lyrEps":0,"shares":194200862,"dividePrice":0,"high":23.99,"amplitude":0,"preClose":23.99,"low":23.99,"week52Low":23.99,"pbRate":"-100.52","week52High":23.99,"institutionHeld":0.5771,"latestPrice":23.99,"eps":-0.18,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.18,"open":23.99,"prevYearClose":23.99,"prevWeekClose":23.99,"prevMonthClose":23.99,"prevQuarterClose":23.99,"fiveDayClose":23.99,"twentyDayClose":23.99,"sixtyDayClose":23.99},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ARIA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2016-11-07","symbol":"ARIA","fiscalQuarterEnding":null,"expectedEps":-0.19,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1478494800000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2016-07-28","symbol":"ARIA","fiscalQuarterEnding":null,"expectedEps":0.57,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1469678400000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2016-05-10","symbol":"ARIA","fiscalQuarterEnding":null,"expectedEps":-0.28,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1462852800000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2016-02-23","symbol":"ARIA","fiscalQuarterEnding":null,"expectedEps":-0.28,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1456203600000,"reportTimeType":"pre","actualEps":-0.32},{"market":"US","date":"2015-11-03","symbol":"ARIA","fiscalQuarterEnding":null,"expectedEps":-0.2,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1446526800000,"reportTimeType":"pre","actualEps":-0.29}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ARIA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ARIA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ARIA\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2564169360","title":"ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310","url":"https://stock-news.laohu8.com/highlight/detail?id=2564169360","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564169360?lang=en_us&edition=fundamental","pubTime":"2025-09-03 19:00","pubTimestamp":1756897200,"startTime":"0","endTime":"0","summary":"Cohort 2 fully enrolled; enrollment and dosing now underway for Cohort 3 (final dose level); No cases of amyloid-related imaging abnormalities (ARIA) observed to date; The trial, expected to enroll 12","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/03/3143435/0/en/ProMIS-Neurosciences-Receives-DSMB-Approval-to-Advance-to-Final-Dose-Escalation-Cohort-in-Phase-1b-Alzheimer-s-Trial-of-PMN310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4526","LU2125909759.SGD","AD","BK4218","BK4595","CAN","LU2211815571.USD","BK4600","USA","LU1923622291.USD","LU2125909916.SGD","BK4143","BK4132","BK4170","LU0053671581.USD","LU0757428866.USD","LU1169590202.USD","BK4023","LU1169589451.USD","PD","LU1815336091.USD","MSA","BK4181","ARIA","LU0728928796.USD","PK"],"gpt_icon":0},{"id":"2564334857","title":"Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status","url":"https://stock-news.laohu8.com/highlight/detail?id=2564334857","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564334857?lang=en_us&edition=fundamental","pubTime":"2025-09-03 07:30","pubTimestamp":1756855800,"startTime":"0","endTime":"0","summary":"LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/02/3143241/0/en/Eisai-Initiated-Rolling-Supplemental-Biologics-License-Application-to-the-U-S-FDA-for-LEQEMBI-IQLIK-lecanemab-irmb-as-a-Subcutaneous-Starting-Dose-for-the-Treatment-of-Early-Alzhei.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4567","BK4588","BK4585","MCI","BK4132","AD","IE00B5TLWC47.USD","ARIA","IE00BYQQ9H92.USD","BK4104","FAST","CAA","IE00BFXG0V08.USD"],"gpt_icon":0},{"id":"2563072015","title":"FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2563072015","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563072015?lang=en_us&edition=fundamental","pubTime":"2025-08-30 05:00","pubTimestamp":1756501200,"startTime":"0","endTime":"0","summary":"LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial treatme","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/29/3141816/0/en/FDA-Approves-LEQEMBI-IQLIK-lecanemab-irmb-Subcutaneous-Injection-for-Maintenance-Dosing-for-the-Treatment-of-Early-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","AAIC","HF","BK4080","MCI","CSF","CAA","CDR","BK4110","ARIA","AD"],"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":20,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ARIA\",params:#limit:6,delay:false,,,undefined,":[]}}